Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Laboratories to settle shareholders' suit for $65 million

This article was originally published in Scrip

Executive Summary

Forest Laboratorieshas reached a tentative settlement of $65 million in a securities class action suit in which it was alleged that the company provided misleading information about the safety of Celexa (citalopram) and Lexapro (escitalopram), according to the law blog productliabilitylaw360. In its most recent 10-Q filing with the SEC, Forest stated that it had entered a memorandum of understanding dated September 22nd with regard to securities litigation, setting forth an agreement in principle to settle all claims for $65 million; details of the litigation were not provided. "While we believe the settlement is covered by our insurance and we are engaged in discussions with the carriers concerning the liability for the payment, during the September 2008 quarter we recorded a $25 million reserve in connection with the MOU," the company said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC031954

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel